Cellestia Biotech

Excited to present Cellestia Biotech at Bio 2024. Reach out to learn more about our science and clinical development program at Swiss pavilion (booth 2111).

This week, four Swiss #biotech startups joined us in Boston for a three-day program on their way to the BIO International Convention in San Diego next week. Meet the startups and find out more about their experience in Boston as part of the Innosuisse Internationalization Camps! 🚀 The startups are: Nagi Bioscience, whose SydLab System is a benchtop laboratory device allowing standardized drug and chemical testing on microorganisms within disposable microfluidic cartridges. mimiX Biotherapeutics which has developed FastSkin, a dermal substitute developed by mimiX using their Sound Induced Morphogenesis technology, offers a novel solution to help patients struggling to heal from complex wounds. Cellestia Biotech is a fully integrated R&D company specialized in innovative therapeutics with new modes of action to treat autoimmune diseases and multidrug resistant cancers. Amphilix AG is developing small molecular chimeras utilizing a unique linker platform that enables fine-tuning of molecular properties, raising the bar for standard-of-care treatment and addressing unmet medical needs. Here’s what they’ve been up to this week: ⚖️ In a session on incorporation with Laura Stoffel (Gunderson Dettmer) they discussed types of legal structures in the US and their implications. 👨💻 With Alexander Harrall (TriNet) they learned how to hire in the US and discover cultural differences in the recruitment process to attract the best talent. 📃 James Ravitz (McDermott Will & Emery) shared insights on the FDA’s regulatory approval process and got them ready for expansion. 🧪 With Alberto Nobili, the startups got the chance to tour Bayer Co.Lab, an incubator for early-stage healthcare startups. 👥 In a feedback session with investors Doug Zingale and Edward Melia the startups got invaluable advice on their pitches and practiced how to adjust them to the local audience. 🗃️ In a session on taxation with Gerhard Friedrich Schneiders (Rödl & Partner USA) they discussed differences between Switzerland and the US, and the tax implications of different legal entities. 📣 Finally, with Mehdi Aghdaee, MD, PhD (#QuantLifeSciences), they worked on their storytelling skills, practicing how to create a storyline and capture an audience - which will come in handy next week! We welcomed the startups to the US with our Biotech Garden Party, where they were able to meet and network with members of Boston’s biotech community, including representatives from Novartis, Sanofi, Pfizer, and many others who will be attending #BIO2024. Thanks to all who attended the event, and especially to Innosuisse, Greater Zurich Area, Greater Geneva Bern area (GGBa), and Switzerland Global Enterprise for their partnership. Thank you as well to all the experts who shared their time and knowledge with the startups throughout the week! 🙏🏼 Next stop, San Diego! 🌴 #SwissBiotech #SwissStartups

Thrilled to join the Treg-Directed Therapies Summit alongside industry peers as an Expert Speaker. We will unveil cutting-edge research from Cellestia Biotech on modulating Treg cells to tackle autoimmune diseases. Stay tuned..

I will be attending Bio-Europe in Barcelona. Get in touch to learn more about Cellestia's pipeline and innovative approach to address autoimmune and inflammatory diseases. Informa Connect

Follow Raj Lehal, PhD, Cellestia Biotech CEO, presenting at the 6th Treg Summit in Boston on May 21-23, 2024! #treg #tregcells #autoimmunity

Cellestia Biotech is proud to announce its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation project to advance to clinical Proof of Concept a first-in-class therapy for prevention of Graft vs Host Disease (GvHD). To read the Press Release: https://lnkd.in/eicS9jwW

Our CEO Raj Lehal, PhD will be attending #jpmorgan week 2024 in San Francisco from January 8-11. Set up a meeting to learn more about Cellestia Biotech and our exciting program!

The Cellestia Biotech team would like to wish you and your loved ones a wonderful holiday season!

I’m looking forward to joining over 650 public & private healthcare companies, institutional and private equity investors, and VCs at the @Jefferies London Healthcare Conference 2023 on November 14 - 16. This year’s gathering will specifically bring together 3,000 leading executives to address near-and long-term investment opportunities as well as the current trends driving healthcare in the U.S. and internationally. #JefferiesHealthcare

https://lnkd.in/eryc2AKg